Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease

Human glutaminyl cyclase (hQC) is drawing considerable attention and emerging as a potential druggable target for Alzheimer's disease (AD) due to its close involvement in the pathology of AD via the post-translational pyroglutamate modification of amyloid-β. A recent phase 2a study has shown pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Daoyuan, Chen, Qingxiu, Qin, Xiaofei, Tong, Peipei, Peng, Liping, Zhang, Tao, Xia, Chunli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Aging Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435661/
https://www.ncbi.nlm.nih.gov/pubmed/37600512
http://dx.doi.org/10.3389/fnagi.2023.1209863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435661/
https://www.ncbi.nlm.nih.gov/pubmed/37600512
http://dx.doi.org/10.3389/fnagi.2023.1209863

Ejemplares similares